Afya Limited (NASDAQ:AFYA) Accelerates Buybacks While Margins Support Near-Term Price Pressure

Afya Limited presents a firm fundamental base and cash generation profile while technical indicators signal short-term downside pressure; corporate buybacks and margin strength alter the balance of risks into the coming weeks.

Recent News

On August 13, 2025 Afya announced second-quarter and first-half 2025 results alongside a Board-approved share repurchase program that may cover up to 4,000,000 Class A shares beginning August 15, 2025 through December 31, 2026. The same announcement noted the closing and integration of an acquisition that adds 60 medical seats and reiterated full-year guidance and cash return priorities.

Technical Analysis

ADX at 15.91 indicates no established trend; price action currently behaves more like a range-bound market than a trending one. That lack of trend tempers the conviction of directional signals while leaving room for range-bound sellers to exert pressure.

Directional indicators show bearish bias: DI+ at 17.89 registered a peak-and-reversal, which indicates DI+ decreasing and therefore a bearish directional shift; DI- at 18.08 registered a dip-and-reversal, which indicates DI- increasing and therefore additional bearish pressure. Together, those moves favor downside over the immediate horizon.

MACD sits at -0.17 with a signal line at -0.14 and a peak-and-reversal in the MACD trend. The MACD below its signal line and a peak-and-reversal trend denote weakening momentum and bearish momentum pressure.

MRO reads 5.5 and trends down. A positive MRO implies price sits above the calculated target and therefore carries potential toward a decrease; the modest absolute value and decreasing trend indicate only limited momentum behind that potential.

RSI at 43.92 with a peak-and-reversal indicates short-term momentum turned lower but has not reached oversold territory. That level allows further downward movement without a technical oversold bounce being compelled.

Price sits at $14.48, below the 20-day average ($14.77), the 50-day average ($15.24) and materially below the 200-day average ($16.57). The 12-day EMA shows a peak-and-reversal, reinforcing short-term weakness. Price trades around the lower Bollinger band: the 1× lower band at $14.51, the 2× lower band at $14.24; the close near those values implies limited immediate downside cushion but proximity to potential short-term support near $14.24.

Ichimoku short-term lines show Tenkan-Sen at $14.78 above the close and Kijun-Sen at $15.31 further above; those levels act as near-term resistance. The SuperTrend upper band at $15.44 also registers overhead resistance. Volume sits roughly in line with short- and mid-term averages, so no breakout-supporting volume currently appears.

 


Fundamental Analysis

Total revenue for the period registers at $919,400,000 with YoY revenue growth of -3.58% and QoQ revenue growth of -1.18%, indicating modest contraction in top-line activity year-over-year and quarter-over-quarter. Gross profit reached $576,693,000 and gross margin measured 62.73%.

Operating income tallied $284,930,000 and EBIT $305,848,000, yielding an EBIT margin of 35.87%. That EBIT margin exceeds the industry peer range high of 25.94% from the available peer comparisons. QoQ the EBIT margin fell by 13.50%, while YoY it improved by 19.63%.

Adjusted EBITDA stands at $400,546,000 with an EBITDA margin consistent with the strong operating margin profile. Net income reached $172,332,000. EPS came in at $2.27 versus an estimate of $2.02, producing an EPS surprise of +$0.25 or +12.38%.

Cash generation shows strength: operating cash flow of $307,746,000 and free cash flow of $178,886,000 produce a free cash flow yield of 12.56%. Free cash flow covers net income at about 104%. Cash and short-term investments total $1,099,107,000, providing liquidity to fund repurchases and operations.

Leverage and coverage portray elevated financial obligation: total debt at $3,225,058,000 and net debt of $1,114,860,000 produce debt-to-EBITDA of 7.60x and an interest coverage ratio of 2.43x. Debt metrics indicate higher leverage relative to operating earnings and tighter interest coverage.

Valuation multiples show a trailing P/E of 7.12 and a price-to-book ratio of 0.31. The price-to-book ratio remains below the industry peer mean of 2.57 and median of 1.73 where peer comparisons exist. Forward EPS of $0.4225 produces a forward P/E of 42.61, reflecting a material step-up in next-period multiple driven by lower forward EPS expectations.

Operational efficiency measures: asset turnover sits at 0.100, return on equity at 3.75% and return on assets at 1.88%. Cash conversion ratios and margins indicate strong cash conversion in the period measured, but returns on invested capital remain conservative relative to margin levels because of large intangible and invested capital balances.

WMDST values the stock as under-valued given current earnings power, margin profile and cash generation; valuation contrasts (trailing P/E, low P/B and high free cash flow yield) drive that determination despite elevated leverage and muted near-term revenue trends.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-08-13
NEXT REPORT DATE: 2025-11-06
CASH FLOW  Begin Period Cash Flow 1.2 B
 Operating Cash Flow 307.7 M
 Capital Expenditures -128.86 M
 Change In Working Capital -110.39 M
 Dividends Paid
 Cash Flow Delta -55.78 M
 End Period Cash Flow 1.1 B
 
INCOME STATEMENT REVENUE
 Total Revenue 919.4 M
 Forward Revenue 51.2 M
COSTS
 Cost Of Revenue 342.7 M
 Depreciation 48.8 M
 Depreciation and Amortization 94.7 M
 Research and Development
 Total Operating Expenses 634.5 M
PROFITABILITY
 Gross Profit 576.7 M
 EBITDA 400.5 M
 EBIT 305.8 M
 Operating Income 284.9 M
 Interest Income 39.5 M
 Interest Expense 111.8 M
 Net Interest Income -92.76 M
 Income Before Tax 194.0 M
 Tax Provision 17.5 M
 Tax Rate 9.0 %
 Net Income 172.3 M
 Net Income From Continuing Operations 194.0 M
EARNINGS
 EPS Estimate 2.02
 EPS Actual 2.27
 EPS Difference 0.25
 EPS Surprise 12.376 %
 Forward EPS 0.42
 
BALANCE SHEET ASSETS
 Total Assets 9.2 B
 Intangible Assets 5.6 B
 Net Tangible Assets -987.52 M
 Total Current Assets 1.9 B
 Cash and Short-Term Investments 1.1 B
 Cash 1.1 B
 Net Receivables 679.0 M
 Inventory
 Long-Term Investments 117.4 M
LIABILITIES
 Accounts Payable 333.3 M
 Short-Term Debt 1.2 B
 Total Current Liabilities 2.0 B
 Net Debt 1.1 B
 Total Debt 3.2 B
 Total Liabilities 4.6 B
EQUITY
 Total Equity 4.6 B
 Retained Earnings 2.3 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 50.90
 Shares Outstanding 90.811 M
 Revenue Per-Share 10.18
VALUATION
 Market Capitalization 1.4 B
 Enterprise Value 3.6 B
 Enterprise Multiple 8.363
Enterprise Multiple QoQ 8.943 %
Enterprise Multiple YoY 165.624 %
Enterprise Multiple IPRWA high: 206.444
mean: 52.953
median: 47.277
AFYA: 8.363
low: -197.551
 EV/R 3.861
CAPITAL STRUCTURE
 Asset To Equity 2.01
 Asset To Liability 2.008
 Debt To Capital 0.412
 Debt To Assets 0.349
Debt To Assets QoQ -0.652 %
Debt To Assets YoY 1576.753 %
Debt To Assets IPRWA high: 1.03
AFYA: 0.349
mean: 0.331
median: 0.32
low: 0.001
 Debt To Equity 0.702
Debt To Equity QoQ -3.563 %
Debt To Equity YoY 1608.425 %
Debt To Equity IPRWA high: 4.335
mean: 1.164
median: 1.004
AFYA: 0.702
low: -1.392
PRICE-BASED VALUATION
 Price To Book (P/B) 0.31
Price To Book QoQ -16.767 %
Price To Book YoY -22.38 %
Price To Book IPRWA high: 16.081
mean: 2.571
median: 1.731
AFYA: 0.31
low: -7.254
 Price To Earnings (P/E) 7.119
Price To Earnings QoQ 28.794 %
Price To Earnings YoY -7.474 %
Price To Earnings IPRWA high: 272.225
mean: 63.731
median: 45.616
AFYA: 7.119
low: -187.532
 PE/G Ratio -0.245
 Price To Sales (P/S) 1.549
Price To Sales QoQ -11.463 %
Price To Sales YoY -21.051 %
Price To Sales IPRWA high: 28.322
mean: 5.837
median: 3.432
AFYA: 1.549
low: 0.067
FORWARD MULTIPLES
Forward P/E 42.609
Forward PE/G -1.466
Forward P/S 27.99
EFFICIENCY OPERATIONAL
 Operating Leverage 8.318
ASSET & SALES
 Asset Turnover Ratio 0.1
Asset Turnover Ratio QoQ -3.995 %
Asset Turnover Ratio YoY -3.848 %
Asset Turnover Ratio IPRWA high: 1.071
median: 0.385
mean: 0.338
AFYA: 0.1
low: 0.001
 Receivables Turnover 1.397
Receivables Turnover Ratio QoQ -8.008 %
Receivables Turnover Ratio YoY -2.4 %
Receivables Turnover Ratio IPRWA high: 12.053
mean: 4.142
median: 2.957
AFYA: 1.397
low: 0.065
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 65.299
CASH CYCLE
 Cash Conversion Cycle Days (CCC)
Cash Conversion Cycle Days QoQ
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA
CAPITAL DEPLOYMENT
 Cash Conversion Ratio -7.17
 CapEx To Revenue -0.14
 CapEx To Depreciation -1.361
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 5.6 B
 Net Invested Capital 6.8 B
 Invested Capital 6.8 B
 Net Tangible Assets -987.52 M
 Net Working Capital -128.22 M
LIQUIDITY
 Cash Ratio 0.546
 Current Ratio 0.936
Current Ratio QoQ -34.158 %
Current Ratio YoY -36.406 %
Current Ratio IPRWA high: 8.204
mean: 1.404
AFYA: 0.936
median: 0.838
low: 0.225
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA 7.597
 Cost Of Debt 3.846 %
 Interest Coverage Ratio 2.429
Interest Coverage Ratio QoQ -33.393 %
Interest Coverage Ratio YoY -22.438 %
Interest Coverage Ratio IPRWA high: 34.501
mean: 5.041
median: 3.159
AFYA: 2.429
low: -51.12
 Operating Cash Flow Ratio 0.118
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 105.727
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 1.386 %
 Revenue Growth -1.811 %
Revenue Growth QoQ -117.603 %
Revenue Growth YoY -357.61 %
Revenue Growth IPRWA high: 17.881 %
median: 4.575 %
mean: 3.504 %
AFYA: -1.811 %
low: -32.565 %
 Earnings Growth -29.063 %
Earnings Growth QoQ -155.484 %
Earnings Growth YoY 76.965 %
Earnings Growth IPRWA high: 250.0 %
mean: -19.312 %
median: -19.556 %
AFYA: -29.063 %
low: -291.304 %
MARGINS
 Gross Margin 62.725 %
Gross Margin QoQ -10.155 %
Gross Margin YoY 2.618 %
Gross Margin IPRWA high: 88.057 %
AFYA: 62.725 %
mean: 28.065 %
median: 27.838 %
low: -9.108 %
 EBIT Margin 35.873 %
EBIT Margin QoQ -13.499 %
EBIT Margin YoY 19.632 %
EBIT Margin IPRWA AFYA: 35.873 %
high: 25.937 %
mean: 7.134 %
median: 4.905 %
low: -48.909 %
 Return On Sales (ROS) 31.023 %
Return On Sales QoQ -25.194 %
Return On Sales YoY 3.458 %
Return On Sales IPRWA AFYA: 31.023 %
high: 25.937 %
mean: 8.027 %
median: 6.654 %
low: -49.228 %
CASH FLOW
 Free Cash Flow (FCF) 178.9 M
 Free Cash Flow Yield 12.561 %
Free Cash Flow Yield QoQ -49.518 %
Free Cash Flow Yield YoY -2.681 %
Free Cash Flow Yield IPRWA AFYA: 12.561 %
high: 10.465 %
mean: 1.637 %
median: 1.538 %
low: -16.999 %
 Free Cash Growth -56.116 %
Free Cash Growth QoQ -158.832 %
Free Cash Growth YoY 52.142 %
Free Cash Growth IPRWA high: 390.254 %
AFYA: -56.116 %
mean: -64.727 %
median: -66.168 %
low: -877.035 %
 Free Cash To Net Income 1.038
 Cash Flow Margin 25.735 %
 Cash Flow To Earnings 1.373
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 1.878 %
Return On Assets QoQ -33.143 %
Return On Assets YoY -7.76 %
Return On Assets IPRWA high: 5.204 %
AFYA: 1.878 %
mean: 1.023 %
median: 0.951 %
low: -16.328 %
 Return On Capital Employed (ROCE) 4.564 %
 Return On Equity (ROE) 0.037
Return On Equity QoQ -34.527 %
Return On Equity YoY -5.662 %
Return On Equity IPRWA high: 0.111
AFYA: 0.037
median: 0.025
mean: 0.024
low: -0.486
 DuPont ROE 3.831 %
 Return On Invested Capital (ROIC) 4.407 %
Return On Invested Capital QoQ -17.703 %
Return On Invested Capital YoY -110.357 %
Return On Invested Capital IPRWA high: 7.951 %
AFYA: 4.407 %
median: 1.954 %
mean: 1.535 %
low: -22.946 %

Six-Week Outlook

Technical indicators point to near-term downside bias: directional indicators, MACD below its signal line, a falling MRO and an RSI that has rolled over favor consolidative or lower price behavior. Price trading below short- and medium-term averages and near the lower Bollinger band increases the probability of continued selling pressure unless buyback activity or a volume-backed reversal emerges.

Fundamentals provide a counterweight: strong margins, robust free cash flow generation and $1.10 billion in cash enable the announced repurchase program and create balance-sheet support that can limit sustained deterioration. Elevated debt-to-EBITDA and modest interest coverage create vulnerability to any sudden operational setbacks, however.

Over the next six weeks, expect trading to remain range-bound with a downward tilt absent a significant volume-led reversal; corporate buybacks and margin resilience offer structural support that should compress downside compared with similarly leveraged peers, while technical momentum will likely determine the short-run direction.

About Afya Limited

Afya Limited (NASDAQ:AFYA) is a pioneering force in medical education and digital health services, primarily operating in Brazil. The company is committed to transforming healthcare education through its diverse offerings across three main segments: Undergrad, Continuing Education, and Digital Services. Afya’s educational portfolio includes medical schools, residency preparation courses, and postgraduate programs, designed to nurture the next generation of healthcare professionals. Beyond traditional education, Afya excels in digital innovation, providing subscription-based platforms that empower healthcare professionals and students with essential tools for clinical decision-making. These digital solutions encompass medical calculators, up-to-date medical content, and clinical scoring systems, ensuring that users have the latest resources at their fingertips. Afya’s influence extends across various disciplines, offering courses in medicine, dentistry, nursing, and biomedicine, as well as business, engineering, and law. The company’s digital arm includes cutting-edge solutions like iClinic, a practice management tool; Cliquefarma, a pharmaceutical price comparison platform; Shosp, a clinical management system; RX PRO, a bridge between physicians and the pharmaceutical industry; and Glic, an app for diabetes management. Since its inception in 1999, Afya, headquartered in Nova Lima, Brazil, has been at the forefront of revolutionizing healthcare education and digital services, continually adapting to meet the evolving needs of the medical community.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.